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INTRODUCTION 
The floating sustained release dosage forms present 
most of the characteristics of hydrophilic matrices and 
are known as „hydrodynamically balanced systems‟ 
(„HBS‟) since they are able to maintain their low 
apparent density, while the polymer hydrates and 
builds a gelled barrier at the outer surface.1,2                
The drug is released progressively from the swollen 
matrix, as in the case of conventional hydrophilic 
matrices. These forms are expected to remain buoyant 
(3- 4 hours) on the gastric contents without affecting 
the intrinsic rate of emptying because their bulk 
density is lower than that of the gastric contents.1 
Many results have demonstrated the validity of the 
concept of buoyancy in terms of     prolonged gastric 
retention time of the floating forms, improved 
bioavailability of drugs and improved clinical 
situations. 
These results also demonstrate that the presence of 
gastric content is needed to allow the proper 
achievement of the buoyancy retention principle. 
Among the different hydrocolloids recommended for 
floating form formulations, cellulose ether polymers 
are most popular, especially hydroxypropyl 
methylcelluloses. Fatty material with a bulk density 
lower than one may be added to the formulation to 
decrease the water intake rate and increase buoyancy 
time.1 
Bilayer tablet is new era for developing a combination 
of two or more active pharmaceutical ingredient in 
single dosage form, Promoting patient convenience 
and compliance. Two or more ingredients to be 
formulated together inspite of active having different 
physico-chemical characteristics (active 
incompatibility). Dual release tablet is a unit 
compressed tablet dosage form intended for oral 
application. It contains two layers in which one layer 
having conventional or immediate release part of 
single or multiple actives; another layer is sustained or 
controlled release part of single or multiple actives. 
They are also called as multi-layer matrix tablet.1
 
  
Bi-layer tablet is suitable for sequential release of two 
drugs in combination, separate two incompatible 
substances and also for sustained release tablet in 
which one layer is immediate release as initial dose 
and second layer is maintenance dose.1 
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ABSTRACT 
Aim of study was to develop bilayered floating drug delivery for treatment of hypertension by delivering loading and 
maintenance dose for fast achievement of peak plasma concentration and maintaining the same respectively. The prepared drug 
loaded bilayered floating tablets were evaluated for pre and post compression parameters. Stability study of the promising 
formulation was also performed. The tablets were prepared by direct compression method. The loading dose was delivered in 
the form of immediate release layer prepared by different super-disintegrations and maintenance dose was delivered through 
sustained release layer prepared by using polymers like HPMC K15M and Carbopol 934P. Both the immediate release layer 
and sustained release layers were separately optimized and then combined to optimize the bilayered floating tablets. No 
interactions were found between drug and excipients. Formulation containing crosscarmellose sodium shows immediate drug 
release. Formulation Containing HPMC K15M shows sustained release action and bilayered formulations FB7 shows releases 
up to 12 hours with good buoyancy and total floating time. All the Bilayered floating formulations buoyant up to 12 hrs. 
Bilayered floating tablets with release characteristics offer critical advantages such as, site specificity with improved 
absorption and efficacy. This technology can be inculcated to various medicaments which have stomach as the major site of 
absorption. 
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Chemical name: Cis-(+)-[2-(2-dimethylaminoethyl)-5-
(4-methoxyphenyl) -3-oxo-6-thia-2-azabicyclo [5.4.0] 
undeca-7, 9, 11-trien-4-yl] ethanoate 1 
Diltiazem is similar to other peripheral vasodilators. 
Diltiazem inhibits the influx of extra cellular calcium 
across the myocardial and vascular smooth muscle cell 
membranes possibly by deforming the channel, 
inhibiting ioncontrol gating mechanisms, and/or 
interfering with the release of calcium from the 
sarcoplasmic reticulum. The decrease in intracellular 
calcium inhibits the contractile processes of the 
myocardial smooth muscle cells, causing dilation of the 
coronary and systemic arteries, increased oxygen 
delivery to the myocardial tissue, decreased total 
peripheral resistance, decreased systemic blood pressure, 
and decreased afterload.1,2 
FORMULATION 
Table 1: Formulation of Immediate Release Tablets 
Ingredients (mg) 
F1 
 
F2 
 
F3 
 
F4 
 
F5 
 
F6 
 
F7 
 
F8 
 
Diltiazem  HCL 30 30 30 30 30 30 30 30 
Sodium starch glycolate 10 20 - - - - - - 
Croscarmellose Sodium - - 10 20 - - - - 
Crospovidone - - - - 10 20 - - 
Sodium bicarbonate - - - - - - 10 20 
Micro crystalline cellulose 60 50 60 50 60 50 60 50 
Total 100 100 100 100 100 100 100 100 
 
Table 2: Formulation of Sustained Release Floating Tablets 
Ingredients (mg) F9 F10 F11 F12 F13 F14 F15 F16 
Diltiazem HCL 60 60 60 60 60 60 60 60 
HPMC K15M 75 150 75 150 75 150 75 150 
Sodium bi carbonate 10 10 20 20 10 10 20 20 
Tartaric acid 10 10 10 10 20 20 20 20 
Microcrystalline cellusoe 141 66 131 56 131 56 121 46 
Mg. Stearate 2 2 2 2 2 2 2 2 
Talc 2 2 2 2 2 2 2 2 
Total (mg) 300 300 300 300 300 300 300 300 
 
Table 3: Formulation of Bilayered Floating Tablets 
Ingredients (mg) FB1 FB2 FB3 FB4 FB5 FB6 FB7 FB8 
                                                                Immediate Release 
Diltiazem HCL 30 30 30 30 30 30 30 30 
Croscarmellose sodium 10 10 10 10 10 10 10 10 
                                                        Sustained Release 
Diltiazem Hcl 60 60 60 60 60 60 60 60 
HPMC K15M 75    150 75    150 75    150 75    150 
Sodium bi carbonate 10 10 20 20 10 10 20 20 
Tartaric acid 10 10 10 10 20 20 20 20 
Microcrystalline cellulose    151 76    141 66    141 66    121 56 
Mg. Stearate 2 2 2 2 2 2 2 2 
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1. post-compression parameters: immediate release  tablets 
 
2. post-compression parameters: for sustained release floating tablets 
Batch  
Weight Variation  
(mg) (n=3) 
Thickness  
(mm)  
Hardness  
(kg/cm
2
)(n=3)  
Buoyancy Lag 
time  
(sec)  
% Swelling 
F9  300.0±1.92  3.21±0.04  5.4±0.13  99  96.98 
F10  299.5±196  3.22±002  50±0.05  78  97.1 
F1l  300,3±1,58  3.23±0.01  5,9±0,19  65  97.57 
F12  304 ±1.62  3.26±0.09  6.2±0.24  101  97.79 
F13  299.6±1.72  3.10±0.05  6.7±0.15  89  98.11 
F14  3003±158  3.11±003  5.1±0.12  120  98.15 
F15  300.1±1.55  3.10±0.07  5.2±.07  108  99.8 
F16  300.0 ±1.78  3.12±0.08  5.0±.03  109  99.11 
 
3. post compression parameters: for bilayered floating tablets 
Batch  
Weight Variation  
(mg) (n=3) 
Thickness  
(mm)  
Hardness  
(kg /cm
2
)  
Buoyancy lag rime  
(sec)  
FB1  350.00±085  351±004  50±013  100  
FB2  349.08±0.74  352±0.02  5.1±0.05  99  
FB3  35010±099  3A9±0O1  5.3±019  66  
FB4  3495O±0.91  358±0O9  59±024  102  
FB5  349.90±1.12  3.67±0.05  5.7±0.15  101  
FB6  350.00±0.79  3.66±0.03  5.2±0.12  115  
FB7  350.09 ±0.77  369±007  50±018  105  
FB8 350.00±1.78  3.78±0,08  5.6±0.11  110  
  
EVALUATION STUDY
1,2
 
1. Hardness 
The resistance of tablets to breakage under the conditions 
of storage, transportation and handling before usage 
depends on its hardness. The hardness of tablet of each 
formulationwas measured by Monsanto hardness tester.1 
2. Friability 
Friability was measured by Roche friability tester. 10 
tablets were kept in the friability tester and it was rotated 
at 25 rpm for 4 minutes. Initial and final weights were 
then recorded and friability was calculated by following 
formula.2 
Friability= Initial weight-Final weight/ Initial weight 
×100 
3. Weight variation test 
To study weight variation, 20 tablets were taken and 
were weighed individually and the weight variation was 
calculated with the use of standard deviation weight 
values were reported in mg.1 
4. In vitro drug release studies:  
In Vitro drug release studies were performed using USP 
dissolution test apparatus (Type 2). The dissolution 
studies were performed in 900 ml of 1.2 pH dissolution 
medium which was stirred at 50 rpm at 37±0.5°C.1 
5. Swelling index 
Swelling index was done on the prepared tablet by using 
200ml beaker containing 0.1NHCL.The Temperature 
maintained at 370 C .the tablets were tested for 12hrs.the 
-tablets were carefully removed using a small basket, and 
the weight of each tablet was determined. 2 
                             Swelling index = (Wt – W0) x W0 / 
100 
Where,   Wt=Weight of tablet at time t, W0 = Initial 
weight of tablet at 0 time 
Batch  
Weight Variation  
(mg) (n=3) 
Thickness  
(mm)  
Hardness  
(kg/cm
2
)(n=3)  
Disintegration time  
(sec)  
Fl  100.0±1.92  1.80±0.02  4.4±0.12  79.66±1.32  
F2  100.2 ±1.93  1.12±0.04  4.3=0.05  58.00±1.00  
F3  1011±1.77  1.75±0.07  4.8=0.16  4800=1.57  
F4  100.3 ±1.25  1.26=0.09  4.5=0.25  84.33=1.98  
F5  103.5±2.72  1.92±0.03  4.7±0.15  73.30±1.63  
F6  102.3±1.98  1.65±005  4.9±0.10  75.33±1.51  
F7  102.1 ±1.85  1.70±0.08  4.2±0.05  62.33±1.84  
F8  102.4 =1.98  1.90±0.0 1  4.0=0.03  64.34=1.72  
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6. Buoyancy lag time 
It is determined in order to assess the time taken by the 
dosage form to float on the top of the dissolution 
medium, after it is placed in the medium. The tablets 
were placed in a 100 ml glass beaker containing 0.1M 
HCL as per IP. The time required for the tablet to rise to 
the surface and float was determined as floating lag time. 
2 
7. Floating time 
Test for buoyancy is usually performed in Simulated 
Gastric Fluid maintained at 370C. The time for which the 
dosage form continuously floats on the dissolution media 
is termed as floating time. 2 
8. Stability studies 
The optimized formulation was charged for the 
accelerated stability studies according to ICH guidelines 
(40 ± 2ºC and 75 ± 5% RH) for a period of 3 months in a 
stability chamber. The optimized formulations were 
placed in USP type-I flint vials and hermetically closed 
with bromobutyl rubber plugs and sealed with aluminum 
caps. The samples were withdrawn at 30, 60 and 90 days 
and evaluated for the drug content and In Vitro drug 
release.2,20 
9. In Vitro Drug Release 
1. Immediate release 
 
Figure 1: % Cumulative drug release for F1-F4 
 
Figure 2: %Cumulative drug release for F5-F8 
2. Sustained release 
 
Figure 3:   %Cumulative drug release for F9-F16 
3. Bilayered release  
 
Figure 4: % Cumulative drug release for FB1-FB8
 
6. Stability study 
Formulation code Parameter Storage time 
 
FB7 
 
Drug content 
(%) 
Initial 1 month 2 months 3 months 
99.97 99.60 99.45 98.05 
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Figure 5:  %Cumulative drug release for FB7 
 
  CONCLUSION 
Bilayer floating tablet of Diltiazem HCl tablet was 
prepared by direct compression method. The Tablets 
Containing HPMC K15M polymer Showed The high 
degree of swelling. All the floating formulations buoyant 
up to 12 Hr. Formulation F15 containing HPMC K15M 
show better sustained release action. Formulations FB7 
releases up to 12 hours and it shows good buoyancy and 
total floating time. Bilayered floating tablets with release 
characteristics offer critical advantages such as, site 
specificity with improved absorption and efficacy. This 
technology can be inculcated to various medicaments 
which have stomach as the major site of absorption. 
REFERENCES  
1. Seth P Tossounian J, “The hydrodynamically balanced system 
HBS
TM
, A novel drug   delivery system for oral use.”Drug 
Dev.Ind.Pharm.1984,10,313-339 
2. Lachman L, Liberman H Koing J, The theory and Practice of 
Industrial Pharmacy,3
rd
 Ed.Vargheese Publishing 
House,Bombay,1991,430 
3. Yie WC,Text Book of Novel drug delivery system, 2
nd
 Marcel 
Dekker Inc.New York,1992,2 
4. Desai S and Bolton S, A Floating Controlled Release Drug 
Delivery System: In vitro–In vivo Evaluation. Pharmaceucal 
ti. Res., 1993, 10, 321-325. 
5. Panchal HA, Tiwari A, A novel approach of bilayer tablet 
technology: A review. Int. Res. J. Pharm., 2012, 3, 44-49 
6. Pujara ND, Gokani RK, Paun JS, Bilayer tablet – an emerging 
trend., Int. J. pharm. Res. Dev. 2012, 4, 102-111 
7. U.S.National library, Drug information, May 2007          
www/in/wikipedia/org/Wiki/Diltiazem 
8. Kumar P.D and Rathnam g ,   Formulation and 
characterization of bilayer floating tablets of ranitidine,  
Rasayn, J.2010,3 ,368-374 
9. Kumar P.D and Rathnam g ,   Formulation and 
characterization of bilayer floating tablets of ranitidine,  
Rasayn, J.2010,3 ,368-374 
10. Hilton AK, Deasy PB, In Vitro and In Vivo Evaluation of an 
Oral Sustained-release Floating Dosage Form of Amoxycillin 
Trihydrate.Int. J. Pharma.1992, 2 , 79-88. 
11. Gowtham. M,  Vasanti S,  Formulation and evaluation of 
Immediate release folic acid tablets, Der.harma.Lettre, 2011, 
3 , 157-162 
12. Santhanalakshmi G, Elango K, Ramesh Kumar K and 
Farheen F, Formulation and Evaluation of Bilayer Floating 
Tablets of Trimetazidine hydrochloride and Metoprolol 
succinate, Ind J Pharm Edu Res, Jul-Sep, 2012,  46, 3  
13. Divya A,K Kavitha,M.rupeshkumar An overview of Bilayer 
tablet technology Journal of Applied pharmaceutical science 
01, 08; 2011: 43-47 
14. Dey Sanjay, Dutta Snigdha, Mazumder Bhaskar, Formulation 
and evaluation of floating matrix tablet of atenolol for gastro 
retentive drug delivery , 4, 3,2012,434 
15. Natarajan R, Kaveri Naveen, Rajndran N N R, Formulation 
and evaluation of    Aceclofenac gastro retentive darug 
delivery system, RJBPS, 2, Jan-March, 767 
16. Z.Rahman,Kumar A, Formulation and Evaluation of Sustain 
released Bilayer tablets  of captopril, Acta.Pharm,2006, 56, 
49-57 
17. Kannan C,  Karunanithi V, Janarthanan S, Dheivasigamani V,  
Formulation and in vitro Evaluation of Gastroretentive 
Rosiglitazone maleate Floating Tablets,  27-28. 
18. Robinson J R, Sustain and Controlled released drug delivery 
system, MarcelDekker, New York,  1987,72-76 
19. Toti U, Aminabhavi T, Modified guar gum matrix tablet for 
controlled release of Diltiazem hydrochloride, J.Controlled 
Release, 2004, 95, 567-577 
20. Aulton M, Pharmaceutics the science of dosage form 
design,1
st
 Ed,ELBS, Hongkong, 1990, 316 
 
 
0
10
20
30
40
50
60
70
80
90
100
0 5 10 15
Initial
1 month
2 month
3 month
STABILITY STUDY  of FB7 BATCH 
TIME (hr)
%
C
D
R
